We are live on ! Find out more
LBPH

Longboard Pharmaceuticals, Inc. Common Stock
LBPH

Delisted

LBPH was delisted on the 29th of November, 2024.

Back to rankings

18 hedge funds and large institutions have $23.3M invested in Longboard Pharmaceuticals, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

5% less funds holding

Funds holding: 19 → 18 (-1)

12% less capital invested

Capital invested by funds: $26.6M → $23.3M (-$3.25M)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Holders
18
Holders Change
-1
Holders Change %
-5.26%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
7
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$857K
2
IHAM
Integral Health Asset Management
New York
+$534K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$15.4K
4
BCM
Bourgeon Capital Management
Connecticut
+$14K
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$4.76K

Top Sellers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
-$419K
2
Millennium Management
Millennium Management
New York
-$268K
3
BCM
Bridgeway Capital Management
Texas
-$181K
4
Bank of America
Bank of America
North Carolina
-$23K
5
TRCT
Tower Research Capital (TRC)
New York
-$2.03K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$6.91M – – –
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$4.78M +$4.76K +1,186 +0.1%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$3.49M +$857K +213,404 +24%
Millennium Management
4
Millennium Management
New York
$3.12M -$268K -66,847 -6%
FCM
5
Farallon Capital Management
California
$2.64M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$999K +$15.4K +3,835 +1%
IHAM
7
Integral Health Asset Management
New York
$792K +$534K +133,000 +121%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$255K +$2.95K +736 +0.9%
TD Asset Management
9
TD Asset Management
Ontario, Canada
$119K – – –
BCM
10
Bridgeway Capital Management
Texas
$79K -$181K -45,000 -64%
LCM
11
Laurion Capital Management
New York
$66.1K – – –
BlackRock
12
BlackRock
New York
$63.6K +$2.5K +623 +3%
BCM
13
Bourgeon Capital Management
Connecticut
$11.4K +$14K +3,500 New
TRCT
14
Tower Research Capital (TRC)
New York
$9K -$2.03K -505 -15%
UBS Group
15
UBS Group
Switzerland
$3.17K +$3.9K +971 New
Wells Fargo
16
Wells Fargo
California
$189 +$4 +1 +2%
Bank of America
17
Bank of America
North Carolina
$36 -$23K -5,728 -100%
Morgan Stanley
18
Morgan Stanley
New York
$10 – – –
O
19
OrbiMed
New York
– -$422 -113,500 Closed
Citigroup
20
Citigroup
New York
– -$419K -112,605 Closed

LBPH Hedge Fund Activity: Q4 2022 in Review

18 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Longboard Pharmaceuticals, Inc. Common Stock (LBPH) for Q4 2022, worth a combined $23.3M — down 12% from $26.6M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of LBPH and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 7 added.

The largest buyer was Fidelity Investments, adding an estimated $857K. The largest seller was Citigroup, exiting entirely with an estimated $419K sold.

  • 18 institutional investors held Longboard Pharmaceuticals, Inc. Common Stock (LBPH) as of Q4 2022, down from 19 in Q3 2022.
  • Funds reported $23.3M of Longboard Pharmaceuticals, Inc. Common Stock stock for Q4 2022, down 12% quarter-over-quarter.
  • 2 funds opened new Longboard Pharmaceuticals, Inc. Common Stock positions in Q4 2022 and 3 closed out, a net change of -1 holder.
  • The largest Longboard Pharmaceuticals, Inc. Common Stock buyer in Q4 2022 was Fidelity Investments, an estimated $857K added.
  • The largest Longboard Pharmaceuticals, Inc. Common Stock seller in Q4 2022 was Citigroup, an estimated $419K sold.

Based on aggregated 13F filings for Q4 2022.